INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
February 06, 2024 09:00 ET | INmune Bio, Inc.
Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as...
Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel
August 23, 2021 15:52 ET | Sorrento Therapeutics, Inc.
Rheumatoid Arthritis (RA) is one of many chronic autoimmune conditions affecting over 20 million people in the United States (NIH, 2017).Sofusa is a revolutionary technology which delivers biologic...
GMP Cytokines Market to Outstrip $158.13 Million by 2027 Growing Sturdy at 8.1% CAGR - COVID-19 Impact and Global Analysis by
June 11, 2021 09:38 ET | The Insight Partners
Pune, India., June 11, 2021 (GLOBE NEWSWIRE) -- GMP Cytokines Market: Key InsightsAccording to our new research study on “GMP Cytokines Market to 2027 – Global Analysis and Forecast – by Type,...
Enosi Life Sciences Files Patent for TNF-Inhibiting Molecules EN1001, EN2001 and EN3001
November 18, 2020 09:00 ET | Enosi Life Sciences
SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enosi Life Sciences Corp. (“Enosi” or the “Company”), a drug research and development company focused on providing industry-leading therapeutics for...
Therapeutic Antibody Pioneers Professor Sir Marc Feldmann and Dr. H. Michael Shepard Formally Launch Enosi Life Sciences
September 02, 2020 09:00 ET | Enosi Life Sciences
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- World-renowned scientists Professor Sir Marc Feldmann and Dr. H. Michael Shepard are pleased to announce the formal launch of Enosi Life Sciences...